How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

In an interview with Bloomberg News, Viehbacher likened the future of Alzheimer’s treatment to other complex diseases that require multiple drugs with different mechanisms of action.

He suggested Biogen “might” consider testing its Alzheimer’s drug Leqembi alongside Novo’s therapy if trial results are positive. However, he cautioned that Alzheimer’s studies can take years, making the timing of such research ...